Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06613230 | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect | completed | — | 490 | Region SkaneOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | completed | Phase 1 | 29 | Pacylex PharmaceuticalsINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors(NeuroTox-L) |
| completed |
| N/A |
| 40 |
| Centre Hospitalier Régional d'OrléansOTHER |
| 1 |
| Apr 17, 2025 |
| clinicaltrials |
| NCT00511082 | Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | completed | Phase 1 | 7 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04886622 | A Study of DT2216 in Relapsed/Refractory Malignancies | completed | Phase 1 | 20 | Dialectic Therapeutics, IncINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03288974 | Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea(Pomalyst PMS) | completed | — | 397 | CelgeneINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03813147 | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT03301493 | Genomic Testing and Resulting Medical Decisions | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03515174 | Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO | completed | N/A | 70 | National Cancer Centre, SingaporeOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05190068 | HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 89 | HutchmedINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06914700 | A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:(PCNSL，GLIOMA) | completed | — | 800 | Guangdong Provincial People's HospitalOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT01892371 | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | completed | Early Phase 1 | 15 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | completed | Phase 1 | 55 | Washington University School of MedicineOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04317066 | A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) | completed | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | completed | Phase 2 | 178 | Hutchison Medipharma LimitedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02616965 | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma(NIVAHL) | completed | Phase 2 | 110 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 10 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Apr 3, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT06904859 | The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 50 | Shenzhen University General HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT01085617 | Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia(UKALL14) | completed | — | — | University College, LondonOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT02852486 | Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response(EDI-PIO) | completed | Phase 2 | 31 | University of Campinas, BrazilOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03098589 | Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | completed | — | 1,149 | CelgeneINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03700450 | Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 37 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT02555839 | Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice | completed | — | 127 | CelgeneINDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03442673 | Chemotherapy and G-CSF for Mobilization(MOCCCA) | completed | Phase 2 | 137 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT01877382 | A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 107 | Daiichi SankyoINDUSTRY | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06892119 | Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 6 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT01163357 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02744612 | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 39 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03200977 | Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab | completed | — | 95 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00120263 | Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma | completed | N/A | 92 | London Health Sciences CentreOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT03690115 | Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients(PONALLO) | completed | Phase 2 | 23 | Versailles HospitalOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04277442 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | completed | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04646304 | Motion Capture as a Tool for the Assessment of Laparoscopic Performance | completed | N/A | 26 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT05166135 | Latin American Real-world Study in Acute Leukemia(LOYAL) | completed | — | 589 | PfizerINDUSTRY | 4 | Mar 25, 2025 | clinicaltrials |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 37 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03792256 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | completed | Phase 1 | 12 | Children's Oncology GroupNETWORK | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01476839 | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01518556 | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia(IDAML) | completed | Phase 1 / Phase 2 | 49 | Konkuk University Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01758328 | Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02342782 | Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Apr 18, 2025source: clinicaltrials